Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
microRNAs (miRNAs) are dysregulated in a variety of disease states, suggesting that this newly discovered class of gene expression repressors may be viable therapeutic targets. A microarray of miRNA changes in ALS-model superoxide dismutase 1 (SOD1)(G93A) rodents identified 12 miRNAs as significantly changed. Six miRNAs tested in human ALS tissues were confirmed increased. Specifically, miR-155 was increased 5-fold in mice and 2-fold in human spinal cords. To test miRNA inhibition in the central nervous system (CNS) as a potential novel therapeutic, we developed oligonucleotide-based miRNA inhibitors (anti-miRs) that could inhibit miRNAs throughout the CNS and in the periphery. Anti-miR-155 caused global derepression of targets in peritoneal macrophages and, following intraventricular delivery, demonstrated widespread functional distribution in the brain and spinal cord. After treating SOD1(G93A) mice with anti-miR-155, we significantly extended survival by 10 days and disease duration by 15 days (38%) while a scrambled control anti-miR did not significantly improve survival or disease duration. Therefore, antisense oligonucleotides may be used to successfully inhibit miRNAs throughout the brain and spinal cord, and miR-155 is a promising new therapeutic target for human ALS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“miRNAs are increasingly recognized as key regulators in ALS pathophysiology, including mitochondrial integrity and neuroinflammation, with miR-155 and miR-206 demonstrating pivotal roles in SOD1G93A models [48,49,50,51].”
From Modulation of the miR-485-3p/PGC-1α Pathway by ASO-Loaded Nanoparticles Attenuates ALS Pathogenesis (2026) · cites this paper as [48]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Inhibiting miR-155 significantly delays disease progression in SOD1 G93A mice (Koval et al., 2013;Butovsky et al., 2015).”
From MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models (2017) · cites this paper as Koval et al., 2013
The cited source says what the claim attributes to it.
In the citing paper
“Work from our lab and others found that miR-155, a glialenriched miRNA, is upregulated in the spinal cords of end-stage ALS model (SOD1 G93A ) mice and human autopsy (Koval et al., 2013;Butovsky et al., 2015).”
From MicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models (2017) · cites this paper as Koval et al., 2013
In the citing paper
“Targeting miR-155 in microglia has shown to be a benefit in models of ALS84,195 and is currently being pursued as a possible therapeutic strategy.”
From Microglial signatures and their role in health and disease (2018) · cites this paper as [195]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993) · Cell · doi:10.1016/0092-8674(93)90529-y · Cited by 12,948 · cited 1×
“Since their discovery in 1993 (1), microRNAs (miRNAs) have emerged as key regulators in numerous physiological and pathological processes.”
A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing
Landgraf, P., Rusu, M., Sheridan, R., Sewer, A., Iovino, N., Aravin, A., Pfeffer, S., Rice, A., Kamphorst, A. O., Landthaler, M., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.040 · Cited by 3,626
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,204 · cited 1×
“Anti-miRs have been used safely and effectively in the periphery in recent human clinical trials [NCT00688012 and NCT00979927 (20)], and CSF infusion of antisense oligonucleotides designed to lower mRNA has recently been applied to patients with ALS (21).”
Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia
Boillée, S., Yamanaka, K., Lobsiger, C. S., Copeland, N. G., Jenkins, N. A., Kassiotis, G., Kollias, G., & Cleveland, D. W. (2006) · Science · doi:10.1126/science.1123511 · Cited by 1,623
Zhu, S., Stavrovskaya, I. G., Drozda, M., Kim, B. Y. S., Ona, V., Li, M., Sarang, S., Liu, A. S., Hartley, D. M., Wu, D. C., et al. (2002) · Nature · doi:10.1038/417074a · Cited by 1,067
Inositol phosphatase SHIP1 is a primary target of miR-155
O'Connell, R. M., Chaudhuri, A. A., Rao, D. S., & Baltimore, D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902636106 · Cited by 826 · cited 3×
“Furthermore, quantification of one of these targets, SHIP1, across the CNS demonstrated a significant increase over saline in all areas assayed (Fig.”
microRNA-155 Regulates the Generation of Immunoglobulin Class-Switched Plasma Cells
Vigorito, E., Perks, K. L., Abreu-Goodger, C., Bunting, S., Xiang, Z., Kohlhaas, S., Das, P. P., Miska, E. A., Rodriguez, A., Bradley, A., et al. (2007) · Immunity · doi:10.1016/j.immuni.2007.10.009 · Cited by 763
Current hypotheses for the underlying biology of amyotrophic lateral sclerosis
Rothstein, J. D. (2009) · Annals of Neurology · doi:10.1002/ana.21543 · Cited by 703 · cited 1×
“Amyotrophic lateral sclerosis (ALS; also known as Lou Gehrig’s Disease) is a fatal adult-onset neurodegenerative disease characterized by the selective loss of motor neurons in the spinal cord and brain leading to stiffness, severe muscle weakness and death because of respiratory failure typically within 3–5 years of…”
Miller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., Andres, P. L., Mahoney, K., Allred, P., Alexander, K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70061-9 · Cited by 617
Self-citationJunker, A., Krumbholz, M., Eisele, S., Mohan, H., Augstein, F., Bittner, R., Lassmann, H., Wekerle, H., Hohlfeld, R., & Meinl, E. (2009) · Brain · doi:10.1093/brain/awp300 · Cited by 595 · cited 1×
“Our data clearly identify miR-155 as a promising therapeutic target for ALS and may potentially apply more broadly to neurological disorders where miR-155 is increased including multiple sclerosis (23) and in glioblastoma (24).”
Research works printed but not linked: 2
- Esau, C. (2010) In: Keystone Symposia: Diabetes (Z6). Whistler: British Columbia Canada.
- D'Urso, P.I., D'Urso, O.F., Storelli, C., Mallardo, M., Gianfreda, C.D., Montinaro, A., Cimmino, A., Pietro, C. and Marsigliante, S. (2012) miR-155 4134 Human Molecular Genetics, 2013, Vol. 22, No. 20
Cited by
Microglial signatures and their role in health and disease
Butovsky, O., & Weiner, H. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0057-5 · Cited by 1,046
microRNA dysregulation in neurodegenerative diseases: A systematic review
Juźwik, C. A., S. Drake, S., Zhang, Y., Paradis-Isler, N., Sylvester, A., Amar-Zifkin, A., Douglas, C., Morquette, B., Moore, C. S., & Fournier, A. E. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101664 · Cited by 426
Microglia: Agents of the CNS Pro-Inflammatory Response
Rodríguez-Gómez, J. A., Kavanagh, E., Engskog-Vlachos, P., Engskog, M. K. R., Herrera, A. J., Espinosa-Oliva, A. M., Joseph, B., Hajji, N., Venero, J. L., & Burguillos, M. A. (2020) · Cells · doi:10.3390/cells9071717 · Cited by 365
Targeting mi R‐155 restores abnormal microglia and attenuates disease in SOD 1 mice
Butovsky, O., Jedrychowski, M. P., Cialic, R., Krasemann, S., Murugaiyan, G., Fanek, Z., Greco, D. J., Wu, P. M., Doykan, C. E., Kiner, O., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24304 · Cited by 358
“Our results are consistent with a recent report that anti–miR-155 given in combination both peripherally and into the CNS extended survival in SOD1 mice by 10 days.(54)”
ALS Genes in the Genomic Era and their Implications for FTD
Nguyen, H. P., Van Broeckhoven, C., & van der Zee, J. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.03.001 · Cited by 307
Microglia, Lifestyle Stress, and Neurodegeneration
Madore, C., Yin, Z., Leibowitz, J., & Butovsky, O. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.003 · Cited by 311
Antisense oligonucleotides in therapy for neurodegenerative disorders
Evers, M. M., Toonen, L. J. A., & van Roon-Mom, W. M. C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.03.008 · Cited by 286
MicroRNAs: Roles in Regulating Neuroinflammation
Gaudet, A. D., Fonken, L. K., Watkins, L. R., Nelson, R. J., & Popovich, P. G. (2018) · The Neuroscientist · doi:10.1177/1073858417721150 · Cited by 236
Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases
Schoch, K. M., & Miller, T. M. (2017) · Neuron · doi:10.1016/j.neuron.2017.04.010 · Cited by 274
Self-citationThe involvement of microRNAs in neurodegenerative diseases
Maciotta, S., Meregalli, M., & Torrente, Y. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00265 · Cited by 245
Raman, R., Allen, S. P., Goodall, G., Kramer, S., Ponger, L., Heath, P. R., Milo, M., Hollinger, H. C., Walsh, T., Highley, J. R., et al. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12147 · Cited by 265
microRNA-155 Regulates Alpha-Synuclein-Induced Inflammatory Responses in Models of Parkinson Disease
Thome, A. D., Harms, A. S., Volpicelli-Daley, L. A., & Standaert, D. G. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.3900-15.2016 · Cited by 247
“Several different forms of aggregated -syn have been described as activators of microglial cells in vitro (Reynolds et al., 2008a; Reynolds et al., 2008b; Cao et al., 2010; Lee et al., 2010; Harms et al., 2012).”
BackgroundmiR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo
Smith, P. Y., Hernandez-Rapp, J., Jolivette, F., Lecours, C., Bisht, K., Goupil, C., Dorval, V., Parsi, S., Morin, F., Planel, E., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv377 · Cited by 220
“To definewhethermiR-132 treatment could improvememory deficits in diseased mice, miR-132 mimics were delivered into 3xTg-ADmice using osmotic pumps,which allowswidespread delivery in the brain [(54) and Supplementary Material, Fig.”
MethodAmyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era
Paez-Colasante, X., Figueroa-Romero, C., Sakowski, S. A., Goutman, S. A., & Feldman, E. L. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.57 · Cited by 225
Emde, A., Eitan, C., Liou, L., Libby, R. T., Rivkin, N., Magen, I., Reichenstein, I., Oppenheim, H., Eilam, R., Silvestroni, A., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201490493 · Cited by 217
“…were suggested to regulate neuromuscular junction repair (Williams et al , 2009; Valdez et al , 2014), to plausibly regulate neuro-inflammation in ALS (Koval et al , 2013) and may serve as circulating biomarkers (De Felice et al , 2014; reviewed in Droppelmann et al , 2014; Gascon & Gao, 2014).”
Functional roles and networks of non-coding RNAs in the pathogenesis of neurodegenerative diseases
Wu, Y.-Y., & Kuo, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-020-00636-z · Cited by 213
Microglia centered pathogenesis in ALS: insights in cell interconnectivity
Brites, D., & Vaz, A. R. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00117 · Cited by 203
Interplay between MicroRNAs and Oxidative Stress in Neurodegenerative Diseases
Konovalova, J., Gerasymchuk, D., Parkkinen, I., Chmielarz, P., & Domanskyi, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236055 · Cited by 197
ALS: A bucket of genes, environment, metabolism and unknown ingredients
Zufiría, M., Gil-Bea, F. J., Fernández-Torrón, R., Poza, J. J., Muñoz-Blanco, J. L., Rojas-García, R., Riancho, J., & López de Munain, A. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.05.004 · Cited by 194
“It has also been found that other miRNAs, such as miRNA-155, are overexpressed in the spinal cord of patients who died with sporadic or familial ALS (Koval et al., 2013).”
Epigenetic regulation of astrocyte function in neuroinflammation and neurodegeneration
Neal, M., & Richardson, J. R. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.11.004 · Cited by 184
Neuronal dark matter: the emerging role of microRNAs in neurodegeneration
Goodall, E. F., Heath, P. R., Bandmann, O., Kirby, J., & Shaw, P. J. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00178 · Cited by 187
Oligonucleotide therapies for disorders of the nervous system
Khorkova, O., & Wahlestedt, C. (2017) · Nature Biotechnology · doi:10.1038/nbt.3784 · Cited by 179
MiR-155: An Important Regulator of Neuroinflammation
Zingale, V. D., Gugliandolo, A., & Mazzon, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010090 · Cited by 163
Epigenetics Control Microglia Plasticity
Cheray, M., & Joseph, B. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00243 · Cited by 153
“Furthermore, targeting miR-155 appears to restore microglia function and prolongs survival of the SOD1G93A mice (Koval et al., 2013; Butovsky et al., 2015).”
BackgroundMicroRNA-30e regulates neuroinflammation in MPTP model of Parkinson’s disease by targeting Nlrp3
Li, D., Yang, H., Ma, J., Luo, S., Chen, S., & Gu, Q. (2018) · Human Cell · doi:10.1007/s13577-017-0187-5 · Cited by 140
Pinto, S., Cunha, C., Barbosa, M., Vaz, A. R., & Brites, D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00273 · Cited by 135
“Dysregulation of miRNA expression and function in ALS also include elevation of miR-155 in either the rodent ALS model or in the spinal cord tissue of both fALS and sALS patients (Koval et al., 2013).”
BackgroundInfluentialGene therapy for neurodegenerative diseases
O’Connor, D. M., & Boulis, N. M. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.06.001 · Cited by 151
D’Erchia, A. M., Gallo, A., Manzari, C., Raho, S., Horner, D. S., Chiara, M., Valletti, A., Aiello, I., Mastropasqua, F., Ciaccia, L., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10488-7 · Cited by 132
microRNAs as neuroregulators, biomarkers and therapeutic agents in neurodegenerative diseases
Basak, I., Patil, K. S., Alves, G., Larsen, J. P., & Møller, S. G. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2093-x · Cited by 107
Yin, Z., Herron, S., Silveira, S., Kleemann, K., Gauthier, C., Mallah, D., Cheng, Y., Margeta, M. A., Pitts, K. M., Barry, J.-L., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01355-y · Cited by 120
Deregulation of neuronal miRNAs induced by amyloid-β or TAU pathology
Sierksma, A., Lu, A., Salta, E., Vanden Eynden, E., Callaerts-Vegh, Z., D’Hooge, R., Blum, D., Buée, L., Fiers, M., & De Strooper, B. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0285-1 · Cited by 120
Differential expression of miRNA 155 and miRNA 146a in Parkinson's disease patients
Caggiu, E., Paulus, K., Mameli, G., Arru, G., Sechi, G. P., & Sechi, L. A. (2018) · eNeurologicalSci · doi:10.1016/j.ensci.2018.09.002 · Cited by 117
“Numerous studies indicate miR-155 to be over-expressed in inflammatory disorders of the central nervous system such as multiple sclerosis and amyotrophic lateral sclerosis [30].”
BackgroundNew Insights into Oxidative Stress and Inflammatory Response in Neurodegenerative Diseases
Scarian, E., Viola, C., Dragoni, F., Gerlando, R. D., Rizzo, B., Diamanti, L., Gagliardi, S., Bordoni, M., & Pansarasa, O. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052698 · Cited by 129
“MiR-155, involved in inflammatory response and mitochondrial function, was found upregulated in skeletal muscles of ALS patients and in the spinal cord of SOD1 mice [152–154].”
BackgroundCentral nervous system myeloid cells as drug targets: current status and translational challenges
Biber, K. P. H., Möller, T., Boddeke, E., & Prinz, M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.14 · Cited by 116
Jimenez-Mateos, E. M., Engel, T., Merino‐Serrais, P., Fernaud-Espinosa, I., Rodriguez-Alvarez, N., Reynolds, J. R., Reschke, C. R., Conroy, R. M., McKiernan, R. C., DeFelipe, J., et al. (2014) · Brain Structure and Function · doi:10.1007/s00429-014-0798-5 · Cited by 115
Figueroa-Romero, C., Hur, J., Lunn, J. S., Paez-Colasante, X., Bender, D. E., Yung, R., Sakowski, S. A., & Feldman, E. L. (2016) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.12.008 · Cited by 97
“…fluid, and postmortem tissue from ALS subjects (Butovsky et al., 2012; Campos-Melo et al., 2013; De Felice et al., 2012; Freischmidt et al., 2014; Koval et al., 2013a; Kye and Goncalves Ido, 2014; Shinde et al., 2013), results which all support our observed DEmiRNAs in postmortem ALS spinal cord…”
BackgroundResultCurrent Status of microRNA-Based Therapeutic Approaches in Neurodegenerative Disorders
Paul, S., Bravo-Vázquez, L. A., Uribe, S. P., Reyes‐Pérez, P., & Sharma, A. K. (2020) · Cells · doi:10.3390/cells9071698 · Cited by 111
Freischmidt, A., Müller, K., Zondler, L., Weydt, P., Volk, A. E., Božič, A. L., Walter, M., Bonin, M., Mayer, B., von Arnim, C. A. F., et al. (2014) · Brain · doi:10.1093/brain/awu249 · Cited by 98
microRNAs and Neurodegenerative Diseases
Qiu, L., Tan, E., & Zeng, L. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-22671-2_6 · Cited by 110
MiRNA inhibition in tissue engineering and regenerative medicine
Beavers, K. R., Nelson, C. E., & Duvall, C. L. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.12.006 · Cited by 108
Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis
Raheja, R., Regev, K., Healy, B. C., Mazzola, M. A., Beynon, V., Von Glehn, F., Paul, A., Diaz‐Cruz, C., Gholipour, T., Glanz, B. I., et al. (2018) · Muscle & Nerve · doi:10.1002/mus.26106 · Cited by 98
“Among the 23 patients with ALS enrolled, 3 had fALS and 20 had sALS.”
BackgroundInfluentialmiR-155 Is Essential for Inflammation-Induced Hippocampal Neurogenic Dysfunction
Woodbury, M. E., Freilich, R. W., Cheng, C. J., Asai, H., Ikezu, S., Boucher, J. D., Slack, F., & Ikezu, T. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.4790-14.2015 · Cited by 95
“There are no predicted miR-155binding sites in the 3 -UTR of the IL6 mRNA transcript (Griffiths-Jones et al., 2008; Kozomara and Griffiths-Jones, 2014).”
BackgroundNeuroinflammation in motor neuron disease
Endo, F., Komine, O., & Yamanaka, K. (2016) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12309 · Cited by 91
Interplay Between Exosomes, microRNAs and Toll-Like Receptors in Brain Disorders
Paschon, V., Takada, S. H., Ikebara, J. M., de Sousa, É., Raeisossadati, R., Ulrich, H., & Kihara, A. H. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9142-1 · Cited by 100
Gaudet, A. D., Mandrekar-Colucci, S., Hall, J. C. E., Sweet, D. R., Schmitt, P. J., Xu, X., Guan, Z., Mo, X., Guerau-de-Arellano, M., & Popovich, P. G. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0735-16.2016 · Cited by 87
“In the CNS, miR-155-5p is implicated in the onset or progression of amyotrophic lateral sclerosis (Koval et al., 2013) and multiple sclerosis (O’Connell et al., 2010; Murugaiyan et al., 2011; Moore et al., 2013).”
BackgroundParsi, S., Smith, P. Y., Goupil, C., Dorval, V., & Hébert, S. S. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.33 · Cited by 83
Cunha, C., Santos, C., Gomes, C., Fernandes, A. M. A., Correia, A. M., Sebastião, A. M., Vaz, A. R., & Brites, D. M. T. O. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0631-2 · Cited by 94
Neuroinflammation in motor neuron disease.
Komine, O., & Yamanaka, K. (2015) · PubMed · doi:10.18999/nagjms.77.4.537 · Cited by 65
Henry, R. J., Doran, S. J., Barrett, J. P., Meadows, V. E., Sabirzhanov, B. E., Stoica, B. A., Loane, D. J., & Faden, A. I. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0665-9 · Cited by 88
“Inhibition of miR-155 can attenuate toxic neuroinflammatory responses in the CNS [12–14] and improves neurological recovery in experimental models of multiple sclerosis (MS) [15], amyotrophic lateral sclerosis (ALS) [16], neuropathic pain [14], spinal cord injury (SCI) [12], Parkinson’s disease (PD) [17], and ischemic…”
BackgroundDubinsky, A. N., Dastidar, S. G., Hsu, C. L., Zahra, R., Djakovic, S. N., Duarte, S., Esau, C. C., Spencer, B., Ashe, T. D., Fischer, K. M., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.001 · Cited by 83
“86) (Subramanian et al., 2005), in agreement with a previous study reporting global derepression of let-7 targets in the brains of anti-let-7-treated mice (Koval et al., 2013), validating this reagent for let-7 inhibition.”
Self-citationMicroRNA Profiling Reveals Marker of Motor Neuron Disease in ALS Models
Hoye, M. L., Koval, E. D., Wegener, A. J., Hyman, T. S., Yang, C., O'Brien, D. R., Miller, R. L., Cole, T., Schoch, K. M., Shen, T., et al. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3582-16.2017 · Cited by 82
“Inhibiting miR-155 significantly delays disease progression in SOD1G93A mice (Koval et al., 2013; Butovsky et al., 2015).”
BackgroundInfluentialSelf-citationThe roles of microRNAs in spinal cord injury
Shi, Z., Zhou, H., Lu, L., Li, X., Fu, Z., Liu, J., Kang, Y., Wei, Z., Pan, B., Liu, L., et al. (2017) · International Journal of Neuroscience · doi:10.1080/00207454.2017.1323208 · Cited by 86
Gomes, C., Cunha, C., Nascimento, F., Ribeiro, J. A., Vaz, A. R., & Brites, D. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1220-8 · Cited by 79
Amyotrophic Lateral Sclerosis: Molecular Mechanisms, Biomarkers, and Therapeutic Strategies
Yang, X., Ji, Y., Wang, W., Zhang, L., Chen, Z., Yu, M., Shen, Y., Ding, F., Gu, X., & Sun, H. (2021) · Antioxidants · doi:10.3390/antiox10071012 · Cited by 86
Mirnas as Biomarkers of Neurodegenerative Disorders
Viswambharan, V., Thanseem, I., Vasu, M. M., Poovathinal, S. A., & Anitha, A. (2017) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0242 · Cited by 89
Antisense Oligonucleotide-Based Therapies for Diseases Caused by pre-mRNA Processing Defects
Rigo, F., Seth, P. P., & Bennett, C. F. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-1221-6_9 · Cited by 80
ALS and FTD: an epigenetic perspective
Belzil, V. V., Katzman, R. B., & Petrucelli, L. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1587-4 · Cited by 69
“For example, anti-miRs to miR-155 or miR29a extended the lifespans of SOD1-Gly93Ala mice [97, 130].”
BackgroundA Systematic Review of Suggested Molecular Strata, Biomarkers and Their Tissue Sources in ALS
Vijayakumar, U. G., Milla, V., Stafford, M. Y. C., Bjourson, A. J., Duddy, W. J., & Duguez, S. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00400 · Cited by 77
Dysregulated miRNAs as Biomarkers and Therapeutical Targets in Neurodegenerative Diseases
Gentile, G., Morello, G., Cognata, V. L., Guarnaccia, M., Conforti, F. L., & Cavallaro, S. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050770 · Cited by 72
“Increased levels of miR155 were found both in spinal cord tissue and peripheral monocytes of ALS patients and its inhibition increases survival time and disease duration in a murine ALS model, supporting the possibility to use this miRNA as a therapeutical target [212,214,229,247] (Table 3).”
BackgroundInfluentialKovanda, A., Leonardis, L., Zidar, J., Koritnik, B., Dolenc‐Grošelj, L., Kovacic, S. R., Curk, T., & Rogelj, B. (2018) · Scientific Reports · doi:10.1038/s41598-018-23139-2 · Cited by 76
Aberration of miRNAs expression in leukocytes from sporadic amyotrophic lateral sclerosis
Chen, Y., Wei, Q., Chen, X., Li, C., Cao, B., Ou, R., Hadano, S., & Shang, H.-F. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00069 · Cited by 69
“…biogenesis and function (Russell et al., 2012); the anti-miR-155 significantly extends survival and disease duration in the SOD1G93A mouse model (Koval et al., 2013), and the miR-206 delays ALS progression and promotes regeneration of neuromuscular synapses inmice partly through fibroblast…”
BackgroundRegulation of Macrophage, Dendritic Cell, and Microglial Phenotype and Function by the SOCS Proteins
McCormick, S. M., & Heller, N. M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00549 · Cited by 68
“More importantly, systemic delivery of antisense peptide nucleic acids has been effective in rodent models of MS (193, 198, 199), Alzheimer’s disease (200, 201), ALS (202), and ischemic stroke (202).”
BackgroundLaRocca, D., Barns, S., Hicks, S. D., Brindle, A., Williams, J. R., Uhlig, R., Johnson, P. R., Neville, C., & Middleton, F. A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0207785 · Cited by 73
Yelick, J., Men, Y., Jin, S., Seo, S., Espejo‐Porras, F., & Yang, Y. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113414 · Cited by 74
MicroRNA in skeletal muscle development, growth, atrophy, and disease
Kovanda, A., Režen, T., & Rogelj, B. (2014) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1227 · Cited by 81
TDP43 and RNA instability in amyotrophic lateral sclerosis
Weskamp, K., & Barmada, S. J. (2018) · Brain Research · doi:10.1016/j.brainres.2018.01.015 · Cited by 64
“Similar changes in miRNA levels were detected in transgenic mutant SOD1 mouse spinal cord and human ALS monocytes, but not fibroblasts from ALS patients (Butovsky et al. 2012; Koval et al. 2013).”
BackgroundCalió, M. L., Henriques, E., Siena, A., Bertoncini, C. R. A., Gil-Mohapel, J., & Rosenstock, T. R. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00679 · Cited by 64
Matamala, J. M., Arias‐Carrasco, R., Sanchez, C., Uhrig, M., Bargsted, L., Matus, S., Maracaja‐Coutinho, V., Abarzúa, S., van Zundert, B., Verdugo, R. J., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.12.020 · Cited by 72
“exhibit an aberrant expression profile in central nervous system (CNS) tissues from transgenicmousemodels and patients with sALS and fALS (Campos-Melo et al., 2013; Koval et al., 2013).”
BackgroundResultInfluentialIncreased Expression of MicroRNA-29a in ALS Mice: Functional Analysis of Its Inhibition
Nolan, K. B., Mitchem, M. R., Jimenez-Mateos, E. M., Henshall, D. C., Concannon, C. G., & Prehn, J. H. M. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0290-y · Cited by 66
RNA metabolism in ALS: When normal processes become pathological
Droppelmann, C. A., Campos-Melo, D., Ishtiaq, M., Volkening, K., & Strong, M. J. (2014) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2014.881377 · Cited by 63
Micro-RNAs in ALS muscle: Differences in gender, age at onset and disease duration
Pegoraro, V., Merico, A., & Angelini, C. I. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.07.008 · Cited by 67
Motor neuron-derived microRNAs cause astrocyte dysfunction in amyotrophic lateral sclerosis
Hoye, M. L., Regan, M. R., Jensen, L. A., Lake, A. M., Reddy, L. V., Vidensky, S., Richard, J.-P., Maragakis, N. J., Rothstein, J. D., Dougherty, J. D., et al. (2018) · Brain · doi:10.1093/brain/awy182 · Cited by 63
Self-citationThe regulation of exosome function in the CNS: implications for neurodegeneration
Properzi, F., Ferroni, E., Poleggi, A., & Vinci, R. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14204 · Cited by 62
MicroRNA Metabolism and Dysregulation in Amyotrophic Lateral Sclerosis
Rinchetti, P., Rizzuti, M., Faravelli, I., & Corti, S. P. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0537-z · Cited by 69
“Moreover, the anti-miR-155 was able to promote a significant extension in survival time of affected animals [135].”
MicroRNAs in Skeletal Muscle Aging: Current Issues and Perspectives
Jung, H. J., Lee, K., Kwon, K., & Suh, Y. (2018) · The Journals of Gerontology Series A · doi:10.1093/gerona/gly207 · Cited by 62
“In this study using the superoxide dismutase 1 (SOD1)G93A rodents, an amyotrophic lateral sclerosis model, the authors found a significantly extended survival by 10 days and reduced disease duration by 15 days compared to control after treating with antisense miR-155 (53).”
BackgroundMethodRegulatory function of microRNAs in microglia
Brites, D. (2020) · Glia · doi:10.1002/glia.23846 · Cited by 56
Circulating Inflammatory miRNAs Associated with Parkinson’s Disease Pathophysiology
Oliveira, S. R., Dionísio, P. A., Guedes, L. C., Gonçalves, N., Coelho, M. M., Rosa, M. M., Amaral, J. D., Ferreira, J. J., & Rodrigues, C. M. P. (2020) · Biomolecules · doi:10.3390/biom10060945 · Cited by 61
“Of note, numerous studies indicate miR-155 as upregulated in inflammatory conditions, including amyotrophic lateral sclerosis and PD [21,33].”
miR-129-5p: A key factor and therapeutic target in amyotrophic lateral sclerosis
Loffreda, A., Nizzardo, M., Arosio, A., Ruepp, M.-D., Calogero, R. A., Volinia, S., Galasso, M., Bendotti, C., Ferrarese, C., Lunetta, C., et al. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101803 · Cited by 61
Barbosa, M., Gomes, C., Sequeira, C., Gonçalves-Ribeiro, J., Pina, C. C., Carvalho, L. A., Moreira, R., Vaz, S. H., Vaz, A. R., & Brites, D. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.634355 · Cited by 54
Neuroprotective Effect of Bexarotene in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis
Riancho, J., Ruiz-Soto, M., Berciano, M. T., Berciano, J., & Lafarga, M. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00250 · Cited by 56
Marcuzzo, S., Bonanno, S., Kapetis, D., Barzago, C., Cavalcante, P., D’Alessandro, S., Mantegazza, R., & Bernasconi, P. (2015) · Molecular Brain · doi:10.1186/s13041-015-0095-0 · Cited by 56
“Conclusions The aberrant expression of miRNAs in many human diseases [51] makes them potential drug targets, and artificial modulation of dysregulated endogenous miRNAs, through use of antagonists or mimics, is being increasingly considered for therapy [52-55].”
BackgroundReichenstein, I., Eitan, C., Diaz-Garcia, S., Haim, G., Magen, I., Siany, A., Hoye, M. L., Rivkin, N., Olender, T., Toth, B., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav5264 · Cited by 56
Self-citationThe Biomarker and Therapeutic Potential of Mirna in Alzheimer’s Disease
Bekris, L. M., & Leverenz, J. B. (2015) · Neurodegenerative Disease Management · doi:10.2217/nmt.14.52 · Cited by 57
Vaz, A. R., Pinto, S., Ezequiel, C., Cunha, C., Carvalho, L. A., Moreira, R., & Brites, D. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00109 · Cited by 55
“Furthermore, in the mutant SOD1 mouse model, as well as in fALS and sALS patients, miR-155 was found to be elevated and its targeting revealed to restore the dysfunctional microglia and to attenuate disease progression in the ALS mouse model (Koval et al., 2013; Butovsky et al., 2015; Cunha et al., 2018).”
BackgroundThe Biogenesis of miRNAs and Their Role in the Development of Amyotrophic Lateral Sclerosis
Liu, J., Zhou, F., Guan, Y., Meng, F., Zhao, Z., Su, Q., Bao, W., Wang, X., Zhao, J., Huo, Z., et al. (2022) · Cells · doi:10.3390/cells11030572 · Cited by 62
“miR-155 [79] SOD1 G93A mice anti-miR-155 Inhibition of miR-155 extended survival for 10 days and disease duration for 15 days (38%).”
BackgroundGascon, E., & Gao, F.-B. (2014) · Journal of Neurogenetics · doi:10.3109/01677063.2013.876021 · Cited by 52
“Finally, it will be important to further explore potential therapies that target miRNAs, as expression of specifi c miRNAs could largely ameliorate disease symptoms and progression in ALS animal models (Koval et al., 2013; Williams et al., 2009).”
MicroRNAs in the key events of systemic lupus erythematosus pathogenesis
Hušáková, M. (2016) · Biomedical Papers · doi:10.5507/bp.2016.004 · Cited by 56
Anakor, E., Gall, L. L., Dumonceaux, J., Duddy, W. J., & Duguez, S. (2021) · Cells · doi:10.3390/cells10112930 · Cited by 55
MicroRNAs as Potential Circulating Biomarkers for Amyotrophic Lateral Sclerosis
Cloutier, F., Marrero, A., O’Connell, C. M., & Morin, P. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0471-8 · Cited by 56
Quaking andmiR-155interactions in inflammation and leukemogenesis
Tili, E., Chiabai, M. A., Palmieri, D., Brown, M., Cui, R., Fernandes, C., Richmond, T. K., Kim, T., Sheetz, T. J., Sun, H., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5248 · Cited by 52
“As miR-155 expression is elevated in neuro-inflammatory pathologies such as MS or ALS [41, 42], our data further suggest that a lack of QKI anti-inflammatory input may result in the deleterious dominance of miR-155 activity, therefore, miR-155-QKI interactions could prove to be significantly important for future thera…”
The Role of MicroRNAs in Patients with Amyotrophic Lateral Sclerosis
Dardiotis, E., Aloizou, A., Siokas, V., Patrinos, G. P., Deretzi, G., Mitsias, P. D., Aschner, M., & Tsatsakis, A. M. (2018) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1204-1 · Cited by 52
Decoding the Role of Platelets and Related MicroRNAs in Aging and Neurodegenerative Disorders
Espinosa‐Parrilla, Y., González-Billault, C. E., Fuentes, E., Palomo, I. F., & Alarcón, M. A. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00151 · Cited by 50
Induction of miR-155 after Brain Injury Promotes Type 1 Interferon and has a Neuroprotective Effect
Harrison, E. B., Emanuel, K., Lamberty, B. G., Morsey, B. M., Li, M., Kelso, M. L., Yelamanchili, S. V., & Fox, H. S. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00228 · Cited by 48
“, 2014), amyotropic lateral sclerosis (Koval et al., 2013; Parisi et al., 2013; Butovsky et al., 2015b), stroke (Eisenhardt et al.”
Fonseca, Á. Y. G., Martín-Jiménez, C., Barreto, G. E., Aristizábal-Pachón, A. F., & González, J. (2021) · Biomolecules · doi:10.3390/biom11081132 · Cited by 52
Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis
Tosolini, A. P., & Sleigh, J. N. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00405 · Cited by 53
Macro roles for microRNAs in neurodegenerative diseases
Rajgor, D. (2018) · Non-coding RNA Research · doi:10.1016/j.ncrna.2018.07.001 · Cited by 49
Epigenetic Mechanisms of Gene Regulation in Amyotrophic Lateral Sclerosis
Jimenez‐Pacheco, A., Franco, J. M., Lopez, S., Gómez‐Zumaquero, J. M., Leal‐Lasarte, M., Caballero-Hernández, D. E., Cejudo‐Guillén, M., & Pozo, D. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-53889-1_14 · Cited by 47
Management and therapeutic perspectives in amyotrophic lateral sclerosis
Mathis, S., Couratier, P., Julian, A., Vallat, J., Corcia, P., & Masson, G. L. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1227705 · Cited by 51
Pham, J., Keon, M., Brennan, S. E., & Saksena, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103464 · Cited by 45
“The significance of connecting miRNA to the pathology of ALS therefore cannot be underestimated, even beyond SOD1 mutation, particularly when miRNA involved in mitochondrial/oxidative stress such as miR-338-3p [16,104] and miR-142-5p [105,106], and neuroinflammation, like miR-155 [107], have been present amongst both…”
BackgroundChristoforidou, E., Joilin, G., & Hafezparast, M. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01822-4 · Cited by 48
“This overexpression is accompanied by an elevation of all inflammatory miRNAs, as well as several genes associated with neuroinflammation, astrogliosis and microglial activation [207].”
Metadata
- Authors
- Koval, E. D., Shaner, C., Zhang, P., du Maine, X., Fischer, K., Tay, J., Chau, B. N., Wu, G. F., & Miller, T. M.
- Affiliations
- Washington University in St. Louis (US)
- Regulus Therapeutics (United States) (US)
- Corresponding author
- Miller, Timothy M.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-06-04
- Volume
- 22
- Issue
- 20
- Pages
- 4127-4135
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- PMC
- PMC3781640
- OpenAlex
- W2106430667
- Cited by
- 236
- References
- 27
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 11 · 2023: 15 · 2022: 11 · 2021: 15 · 2020: 29 · 2019: 13 · 2018: 30 · 2017: 22 · 2016: 17 · 2015: 27 · 2014: 19 · 2013: 2
- FWCI
- 13.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Human Molecular Genetics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Dana Foundation
- Massachusetts General Hospital
- Edward Mallinckrodt, Jr. Foundation
- National Institutes of Health
- School of Medicine, Stanford University
- National Institute of Neurological Disorders and Stroke (F31NS077781, K08NS062138, K08NS074194, R01NS078398)
- Robert Packard Center for ALS Research, Johns Hopkins University
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Keywords
- miR-155, amyotrophic lateral sclerosis, anti-miR oligonucleotides, microRNA inhibition, SOD1 G93A mice, survival extension, peritoneal macrophages, spinal cord, therapeutic target, antisense oligonucleotides
- MeSH terms
- Adult, Aged, Amyotrophic Lateral Sclerosis, Animals, Brain, Disease Models, Animal, Female, Humans, Male, Mice, Inbred C57BL, Middle Aged, Spinal Cord, Superoxide Dismutase, Case-Control Studies, Oligonucleotides, Antisense, MicroRNAs, Mice, Rats, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.